119434-75-2Relevant articles and documents
Enantioselective synthesis of (S)-3-(4-thiazolyl)-2-tert- butoxycarbonylaminopropionic acid: A chiral building block for renin inhibitor
Yuasa, Yoshifumi,Tsuruta, Haruki,Yuasa, Yoko
, p. 2385 - 2392 (2007/10/03)
(S)-3-(4-Thiazolyl)-2-tert-butoxycarbonylaminopropionic acid (6), an important structural constituent of the renin inhibitor, has been synthesized from (Z)-3-(4-thiazolyl)-2-benzoylaminoprop-2-enoic acid (4b) by enantioselective hydrogenation using the Ru
Peptide derivatives having thiazolyl-alanine residue
-
, (2008/06/13)
A peptide derivation of the formula (I) or its pharmaceutically acceptable salt or hydrate thereof is disclosed. These compounds have superior ability over thyroid stimulating hormone (TRH) and its derivatives to activate the central nervous system, such as, for example, sustained acetylcholine releasing action, anti-reserpine action and locomotor increment.
ENCAPSULATED RENIN INHIBITOR COMPOSITION
-
, (2008/06/13)
A pharmaceutical composition comprising a solution of a tenin inhibitor of the formula: STR1 wherein R 1 is 4-piperazinyl, 1-methyl-4-piperazinyl, 1-methyl-1-oxo-4-piperazinyl, 2-oxo-4-piperazinyl, 4-morpholinyl, 4-thiomorpholinyl or 1-methyl-4-homopiperazinyl; R 2 is benzyl, p-methoxybenzyl, 2-phenylethyl, 1-naphthylmethyl or 2-naphthylmethyl;R 3 is 4-thiazolyl, 2-amino-4-thiazolyl, 2-thiazolyl, 5-thiazolyl, 1-pyrazolyl, 3-pyrazolyl, 1-imidazolyl, n-propyl, isopropyl, CH 3 S--or CH 3 SCH 2--;R 4 is loweralkyl or cyclopropyl;R 5 is hydrogen or loweralkyl; andX is CH 2 or NH; or a pharmaceutically acceptable salt, ester or prodrug thereof in a pharmaceutically acceptable solvent, said solution being encapsulated in a soft elastic gelatin capsule.